MX2023011214A - Tratamiento de la esclerosis lateral amiotrófica. - Google Patents
Tratamiento de la esclerosis lateral amiotrófica.Info
- Publication number
- MX2023011214A MX2023011214A MX2023011214A MX2023011214A MX2023011214A MX 2023011214 A MX2023011214 A MX 2023011214A MX 2023011214 A MX2023011214 A MX 2023011214A MX 2023011214 A MX2023011214 A MX 2023011214A MX 2023011214 A MX2023011214 A MX 2023011214A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- lateral sclerosis
- amyotrophic lateral
- sod1
- presymptomatic
- Prior art date
Links
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 3
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 abstract 2
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 abstract 2
- 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 abstract 1
- 102100023057 Neurofilament light polypeptide Human genes 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3531—Hydrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168972P | 2021-03-31 | 2021-03-31 | |
| PCT/US2022/022485 WO2022212459A1 (en) | 2021-03-31 | 2022-03-30 | Treatment of amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011214A true MX2023011214A (es) | 2023-12-08 |
Family
ID=81346346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011214A MX2023011214A (es) | 2021-03-31 | 2022-03-30 | Tratamiento de la esclerosis lateral amiotrófica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182903A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314294A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024511767A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230172502A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117062911A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022252236A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023019877A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214585A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023011214A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304471A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022212459A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120350010B (zh) * | 2025-06-24 | 2025-09-09 | 羿美诚健(上海)生物医药有限公司 | 靶向PIKfyve基因的小核酸及其药物组合物和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| HUE050704T2 (hu) | 2014-04-01 | 2020-12-28 | Biogen Ma Inc | Összetételek a SOD-1 expressziójának modulálására |
| TWI906204B (zh) * | 2018-12-14 | 2025-12-01 | 美商百健Ｍａ公司 | 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 |
-
2022
- 2022-03-30 BR BR112023019877A patent/BR112023019877A2/pt unknown
- 2022-03-30 JP JP2023557719A patent/JP2024511767A/ja active Pending
- 2022-03-30 CN CN202280024040.2A patent/CN117062911A/zh active Pending
- 2022-03-30 EP EP22717995.9A patent/EP4314294A1/en active Pending
- 2022-03-30 US US18/283,526 patent/US20240182903A1/en active Pending
- 2022-03-30 TW TW111112225A patent/TW202304471A/zh unknown
- 2022-03-30 AU AU2022252236A patent/AU2022252236A1/en active Pending
- 2022-03-30 CA CA3214585A patent/CA3214585A1/en active Pending
- 2022-03-30 WO PCT/US2022/022485 patent/WO2022212459A1/en not_active Ceased
- 2022-03-30 KR KR1020237037099A patent/KR20230172502A/ko active Pending
- 2022-03-30 MX MX2023011214A patent/MX2023011214A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230172502A (ko) | 2023-12-22 |
| WO2022212459A1 (en) | 2022-10-06 |
| US20240182903A1 (en) | 2024-06-06 |
| AU2022252236A1 (en) | 2023-10-12 |
| TW202304471A (zh) | 2023-02-01 |
| CN117062911A (zh) | 2023-11-14 |
| EP4314294A1 (en) | 2024-02-07 |
| AU2022252236A9 (en) | 2023-10-19 |
| BR112023019877A2 (pt) | 2023-11-07 |
| JP2024511767A (ja) | 2024-03-15 |
| CA3214585A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006133052A3 (en) | A cellular therapy for ocular degeneration | |
| WO2021071788A3 (en) | Oligonucleotide compositions and methods of use thereof | |
| WO2020227691A3 (en) | Oligonucleotide compositions and methods of use thereof | |
| MY146937A (en) | Hydrocarbon-soluble molybdenum catalyst precursors and methods of making same | |
| BRPI0506713A (pt) | composições de ácido peroxicarboxìlico de cadeia média | |
| WO2011153553A3 (en) | Methods and compositions for kinase inhibition | |
| MX2023011214A (es) | Tratamiento de la esclerosis lateral amiotrófica. | |
| CO6400140A2 (es) | Derivados de benzotiazol como agentes anticancer | |
| WO2020176654A8 (en) | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents | |
| IN2014DN10996A (cg-RX-API-DMAC7.html) | ||
| MX2011005162A (es) | Proceso para el tratamiento de glicerol. | |
| NZ706745A (en) | Methods of treatment of pancreatic cancer | |
| BR112013003002A2 (pt) | composição contendo aditivo polar e agente quelante útil no hidroprocessamento de suprimentos hidrocarbonetos e método de sua produção e utilização | |
| MY153871A (en) | Isoprene synthase variants for improved microbial production of isoprene | |
| PT1938839E (pt) | Composições oftálmicas de estimulantes parassimpáticos e anti-inflamatórios para utilização no tratamento de presbiopia | |
| MX2009013649A (es) | Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma. | |
| TW200726778A (en) | Compositions and methods for producing silicone hydrogel contact lenses | |
| AR060779A1 (es) | Un metodo para disenar una lente de contacto multifocal que hacen uso de l a apodizacion de la pupila | |
| MX2008010801A (es) | Indolopiridinas como moduladores de quinesina eg5. | |
| CL2022000825A1 (es) | Modificaciones químicas de arn pequeño de interferencia con contenido mínimo de flúor | |
| MX2025004102A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| NZ588999A (en) | Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof | |
| PH12022550124A1 (en) | Enzyme inhibitors | |
| WO2010063630A3 (en) | Pancreatic tumour treatment | |
| MX354827B (es) | Mezcla de policarbonato y metodo de produccion de la misma. |